Document Detail

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
MedLine Citation:
PMID:  16373663     Owner:  NLM     Status:  MEDLINE    
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995, to December 31, 2003. All patients with thalassemia major treated in 7 Italian centers who were born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients, and 157 patients received deferiprone for part of the time. A total of 3,610 patient-years were observed on DFO and 750 on deferiprone. At baseline, the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least 18 months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major.
Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan
Related Documents :
16373663 - Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with t...
7930253 - Variation in utilization of cardiac procedures in the department of veterans affairs he...
17184633 - Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assi...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2005-12-22
Journal Detail:
Title:  Blood     Volume:  107     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-21     Completed Date:  2006-05-24     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3733-7     Citation Subset:  AIM; IM    
Clinica Pediatrica Università di Ferrara, Dipartimento di Medicina Clinica e Sperimentale, Via Fossato di Mortara 17/19, 44100 Ferrara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Deferoxamine / adverse effects,  therapeutic use*
Ferritins / blood
Heart Diseases / etiology*,  mortality,  prevention & control
Iron Chelating Agents / adverse effects,  therapeutic use*
Italy / epidemiology
Pyridones / adverse effects,  therapeutic use*
beta-Thalassemia / blood,  complications*,  drug therapy*
Reg. No./Substance:
0/Iron Chelating Agents; 0/Pyridones; 2BTY8KH53L/deferiprone; 70-51-9/Deferoxamine; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
Next Document:  Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and over...